Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

REMS And Generics: GPhA Needs Legislation, Continues Education

Executive Summary

GPhA says congressional action is only remedy after study estimates $5.4 billion in potential savings is lost annually because of brand manufacturers using REMS to prevent generic competition.

Advertisement

Related Content

Generic Drug Roadblock: 74 Brands Subject To REMS, Other Restrictions
Generic Drug Roadblock: 74 Brands Subject To REMS, Other Restrictions
REMS Reform Seems Distant Goal For Generics After Limited Support At US House Hearing
REMS Reform Seems Distant Goal For Generics After Limited Support At US House Hearing
Sandoz’s Biosimilar Filing Is Culmination Of Paradigm Shift In FDA Drug Review
FDAAA Fading? REMS Use Continues To Decline As Drug Safety Law Matures
Buying Time: Industry Sacrifices Early To Gain Later With PDUFA V Review Model
Did PDUFA V Pass Too Quickly?
GPhA Pushes REMS Pay-for, Schedule III Hydrocodone In User Fee Bill
MedGuide-Only REMS Will Be The Exception, Not The Norm, As FDA Relaxes Policy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS056294

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel